Erratum to: Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases (Journal of Clinical Immunology (2013) 6, (169-178) DOI: 10.1007/s10875-013-9985-z);Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases

Journal of Clinical Immunology

Volumn 34, Issue 2, 2014, Pages 204-211

  Kanegane, Hirokazu ^a   Imai, Kohsuke ^b   Yamada, Masafumi ^c   Takada, Hidetoshi ^d   Ariga, Tadashi ^c   Bexon, Martin ^e   Rojavin, Mikhail ^f   Hu, Wilson ^g   Kobayashi, Midori ^h   Lawo, John Philip ⁱ   Nonoyama, Shigeaki ^j   Hara, Toshiro ^d   Miyawaki, Toshio ^k  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e CSL Behring AG   (Switzerland)

^f CSL Behring LLC   (United States)

^g CSL LIMITED   (Australia)

^h CSL Behring KK   (Japan)

ⁱ CSL BEHRING GMBH   (Germany)

^j NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^k Toyama City Hospital   (Japan)

more..

Author keywords

Hizentra ; IgPro20; Japan; PID; primary antibody deficiency; Primary immunodeficiency; SCIG

Indexed keywords

ANTIBIOTIC AGENT; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GEOMETRIC MEAN RATIO; GEOMETRY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; JAPANESE; MALAISE; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINOPHARYNGITIS; SERUM; SKIN DISEASE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898850033     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0030-7     Document Type: Erratum

References (20)

1. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011;2:54.
2. Notarangelo L, Casanova JL, Fischer A, Puck J, Rosen F, Seger R, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol. 2004;114:677-87.
3. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991;325:110-7.
4. Ishimura M, Takada H, Doi T, Imai K, Sasahara Y, Kanegane H, et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol. 2011;31:968-76.
5. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007;27:497-502.
6. Hagan JB, Fasano MB, Spector S, Wasserman RL, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20 % immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30:734-45.
7. Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141:90-102.
8. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396-404.
9. Ochs HD, Hitzig WH. History of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. 2012;12:577-87.
10. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Am. 2008;28:803-19.
11. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265-73.
12. Borte M, Pac M, Serban M, Gonzalez-Quevedo T, Grimbacher B, Jolles S, et al. Efficacy and safety of Hizentra®, a new 20 % immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol. 2011;31:752-61.
13. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139:133-41.
14. Wasserman RL, Melamed I, Nelson Jr RP, Knutsen AP, Fasano MB, Stein MR, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50:405-14.
15. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93:190-7.
16. U.S. FDA. FDA Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. 2008. http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm078526.pdf 2008. Accessed 29 Jan 2013.
17. Takada H, Kanegane H, Nomura A, Yamamoto K, Ihara K, Takahashi Y, et al. Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation. Blood. 2004;103:185-7.
18. Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. J Infect Chemother. 2002;8:125-33.
19. Sekimoto M, Imanaka Y, Evans E, Ishizaki T, Hirose M, Hayashida K, et al. Practice variation in perioperative antibiotic use in Japan. Int J Qual Health Care. 2004;16:367-73.
20. Ariyanchira S. Antibiotic resistance and antibiotic technologies: global markets. Market research report PHM025B. 2009. http://www.bccresearch.com/ market-research/pharmaceuticals/antibiotic-resistance-technologies-phm025b.html. Accessed 29 Jan 2013.